Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project.
ALCL ALK+ lymphoma
PTCL
outcomes
prospective international T-cell lymphoma project
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
11
08
2022
received:
23
06
2022
accepted:
15
08
2022
pubmed:
10
9
2022
medline:
15
12
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
The T-cell Lymphoma Project is an international registry prospective study that enrolled patients with newly diagnosed peripheral T-cell and NK-cell lymphomas (PTCL). The main objective was to define the clinical features and outcomes, establishing a robust benchmark for future clinical trials. Seventy-four institutions from 14 countries in North America, South America, Europe, and Asia collected data on patients diagnosed and treated at their respective centers between September 2006 and February 2018. Among 1553 PTCL patients, 131 (8.4% of the total cohort) were confirmed to have anaplastic large cell lymphoma - kinase positive (ALCL, ALK+). The median age of the patients was 39 years (18-84). Sixty-five patients (66%) had advanced-stage disease, although majority (45 patients, 54%) had a low-risk International Prognostic Index (IPI) score (0-1). Of 97 patients treated with chemotherapy, 97% received anthracycline-containing regimens. The overall response rate was 81%, with 69 patients (70%) achieving complete remission. Estimated OS and PFS at 3 years were 77% (95% CI: 54%-99%) and 68% (95% CI: 46%-90%), respectively, and at 5 years were very similar, 77% of OS (95% CI: 62%-92%) and 64% of PFS (95% CI: 34%-94%). Multivariate analysis for PFS showed advanced stage (hazard ratios [HR]: 4.72, 95% CI: 1.43-23.9, p = 0.015), elevated lactate dehidrogenade (LDH) (HR 4.85; 95% CI: 1.73-13.60, p = 0.001), and Eastern Cooperative Oncology Group Performance Status scale (ECOG-PS) ≥2 (HR: 5.25; 95% CI: 1.68-16.4, p = 0.024). For OS, elevated LDH (HR: 3.77; 95% CI: 1.98-14.17, p = 0.014) and ECOG-PS ≥2 (HR: 4.59; 95% CI: 1.46-14.39, p = 0.004) were identified. In summary, although the outcome of ALK+ ALCL is superior to that of other PTCLs, it remains sufficiently favorable, given the young median age of the patients. Our results confirm the usefulness of both IPI and Prognostic Index for T-cell Lymphoma (PIT) in identifying groups of patients with different outcomes. Clinical Trials ID: NCT01142674.
Banques de données
ClinicalTrials.gov
['NCT01142674']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
953-961Subventions
Organisme : Fondazione Cassa di Risparmio di Moden; Associazione Angela Serra per la Ricerca sul Cancro, Modena, Italy
Organisme : Fondazione Italiana Linfomi, Alessandria, Italy
Organisme : Allos Therapeutics, Inc., Westminster, CO, USA
Organisme : Spectrum Pharmaceuticals, Inc, Henderson, NV, USA
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. https://doi.org/10.1182/blood-2016-01-643569
Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012;83(2):293-302. https://doi.org/10.1016/j.critrevonc.2012.02.005
Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-858. https://doi.org/10.1182/blood.v66.4.848.848
Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1995;267(5196):316-317.
Morris SW, Xue L, Ma Z, Kinney MC. Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol. 2001;113(2):275-295. https://doi.org/10.1046/j.1365-2141.2001.02574.x
Chiarle R, Martinengo C, Mastini C, et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008;14(6):676-680. https://doi.org/10.1038/nm1769
Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-1036. https://doi.org/10.1182/blood-2009-06-227579
Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117(12):3402-3408. https://doi.org/10.1182/blood-2010-09-310342
Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323-342. https://doi.org/10.1038/s41568-020-0247-0
Vanhentenrijk V, Bempt IV, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C. Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling. J Pathol. 2006;210(2):155-162. https://doi.org/10.1002/path.2043
Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral t-cell lymphoma project. Blood. 2008;111(12):5496-5504. https://doi.org/10.1182/blood-2008-01-134270
Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood. 2010;116(18):3418-3425. https://doi.org/10.1182/blood-2010-02-270785
Khan N, Ozkaya N, Moskowitz A, Dogan A, Horwitz S. Peripheral T-cell lymphoma - are we making progress? Best Pract Res Clin Haematol. 2018;31(3):306-314. https://doi.org/10.1016/j.beha.2018.07.010
Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22(1):29-49. https://doi.org/10.1097/pap.0000000000000047
Jaffe ESHN, Stein H, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: Pathology and Genetics. IARC Press; 2001.
Swerdlow E, Harris NL, Jaffe ES, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press; 2008.
Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):5.
Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229-240.
Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol. 2012;30(32):3939-3946. https://doi.org/10.1200/jco.2012.42.2345
Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507-1517. https://doi.org/10.1002/cncr.31861
García-Sancho AM, Bellei M, López-Parra M, et al. Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. Haematologica. 2022. (in press). https://doi.org/10.3324/haematol.2021.279426
Zing NPC, Fischer T, Zain J, Federico M, Rosen ST. Peripheral T-cell lymphomas: incorporating new developments in diagnostics, prognostication, and treatment into clinical practice-PART 1: PTCL-NOS, FTCL, AITL, ALCL. Oncology. 2018;32(7):e74-e82.
Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474-2479. https://doi.org/10.1182/blood-2003-09-3080
Cederleuf H, Pedersen MB, Jerkeman M, Relander T, d'Amore F, Ellin F. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic lymphoma group study. Br J Haematol. 2017;178(5):739-746. https://doi.org/10.1111/bjh.14740
Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288-298. https://doi.org/10.1016/j.annonc.2021.12.002
Passerini CG, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):djt378. https://doi.org/10.1093/jnci/djt378
Werner MT, Zhang Q, Wasik MA. From pathology to precision medicine in anaplastic large cell lymphoma expressing anaplastic lymphoma kinase (ALK+ ALCL). Cancers (Basel). 2017;9(10):138. https://doi.org/10.3390/cancers9100138
Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23. https://doi.org/10.1038/nrc2291
Astone GCL, Chiu W, Kayembe C, et al. Selective STAT3 degraders dissect peripheral t-cell lymphomas vulnerabilities empowering personalized regimens. Blood. 2021;138((Suppl 1)):865. https://doi.org/10.1182/blood-2021-153995
Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-delta, gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888-898. https://doi.org/10.1182/blood-2017-08-802470
Bai L, Zhou H, Xu R, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell. 2019;36(5):498-511. https://doi.org/10.1016/j.ccell.2019.10.002